# Non-allergic severe asthma – is it really always non-allergic? The IDENTIFY project

Dirk Koschel, Claudia Mailänder, Inessa Schwab Sauerbeck, Jens Schreiber

## Additional file 1

## Methods

Supplementary Table 1. Perennial aeroallergens used for sensitization testing.

| **Class of aeroallergen**  | **Species of aeroallergen** | **Name of aeroallergen** |
| --- | --- | --- |
| House dust mites  | *Dermatophagoides pteronyssinus*  | d1 |
|  | *Dermatophagoides farinae*  | d2 |
|  | *Dermatophagoides microceras*  | d3 |
| Storage mites  | *Lepidoglyphus destructor*  | d71 |
|  | *Glycophagus domesticus*  | d73 |
|  | *Tyrophagus putrescentiae* | d72 |
|  | *Acarus siro*  | d70 |
|  | *Euroglyphus maynei*  | d74 |
|  | *Blomia tropicalis*  | d201 |
| Molds/microorganisms  | *Aspergillus fumigatus*  | m3 |
|  | *Aspergillus niger*  | m207 |
|  | *Staphylococcus aureus* Enterotoxin A  | m80 |
|  | *Staphylococcus aureus* Enterotoxin B  | m81 |
|  | *Cladosporium herbarum*  | m2 |
|  | *Penicillium chrysogenum*  | m1 |
|  | *Alternaria alternata*  | m6 |
|  | *Aspergillus flavus*  | m228 |
|  | *Aspergillus terreus*  | m36 |
|  | *Mucor racemosus*  | m4 |
|  | *Rhizopus nigricans*  | m11 |
|  | *Phoma betae*  | m13 |
|  | *Aureobasidium pullulans*  | m12 |
|  | *Penicillium glabrum*  | m209 |
|  | *Candida albicans*  | m5 |
|  | *Setomelanomma rostrata*  | m8 |
|  | *Chaetomium globosum*  | m208 |
| Animal epithelia  | Cat dander | e1 |
|  | Dog dander  | e5 |
|  | Horse dander  | e3 |
|  | Bovine epithelia | e4 |
|  | Guinea pig epithelia  | e6 |
|  | Hamster epithelia  | e84 |
|  | Mice epithelia  | e71 |
| Insects | Moth (*Bombyx mori*)  | i8 |
|  | Cockroach  | i6 |

## Results

Supplementary Table 2. Demography and disease characteristics.

|  | **All patients(N=454)** |
| --- | --- |
| Gender, male, n (%) | 170 (37.4) |
| Age, years, mean±SD | 56.4±13.7 |
| Body mass index, kg/m2, mean±SD | 27.6±5.9 |
| Smoking status, n (%) |  |
| Non-smoker | 238 (52.4) |
| Ex-smoker | 178 (39.2) |
| Current smoker | 38 (8.4) |
| Asthma duration, years, mean±SD | 13.2±11.4 |
| Age at diagnosis, n (%) |  |
| <12 years | 35 (7.7) |
| ≥12 years | 417 (92.3) |
| GINA asthma control level, n (%) |  |
| Controlled | 55 (12.1) |
| Partly controlled | 168 (37.0) |
| Uncontrolled | 231 (50.9) |
| Exacerbations in the previous 12 months, n (%) |  |
| 0 | 112 (24.7) |
| 1 | 106 (23.3) |
| ≥2 | 226 (49.8) |
| Total IgE, kU/L, mean±SD | 422.0±2634.3(n=372) |
| Asthma maintenance therapy, n (%) |  |
| Inhaled corticosteroid | 448 (98.7) |
| Long-acting beta2 agonist | 436 (96.0) |
| Long-acting muscarinic antagonist  | 243 (53.5) |
| Systemic steroid | 147 (32.4) |
| Leukotriene receptor antagonist | 150 (33.0) |
| Xanthine derivative | 36 (7.9) |

Abbreviations: GINA, Global Initiative for Asthma; IgE, immunoglobulin E